FNY Investment Advisers LLC bought a new stake in scPharmaceuticals Inc. (NASDAQ:SCPH – Get Rating) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,500 shares of the company’s stock, valued at approximately $154,000. FNY Investment Advisers LLC owned about 0.08% of scPharmaceuticals at the end of the most recent reporting period.
→ Will Biden start Operation “Choke Point” in America? (From Investor Place Media)
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in scPharmaceuticals in the second quarter valued at about $53,000. Cubist Systematic Strategies LLC bought a new position in shares of scPharmaceuticals in the third quarter valued at $75,000. State Street Corp increased its holdings in shares of scPharmaceuticals by 15. 0% in the second quarter. State Street Corp now owns 17,360 shares of the company’s stock valued at $84,000 after acquiring an additional 2,260 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in scPharmaceuticals during the third quarter valued at approximately $92,000. Finally, Ritholtz Wealth Management purchased a new position in scPharmaceuticals during the third quarter valued at approximately $98,000. Hedge funds and other institutional investors own 53.90% of the company’s stock.
scPharmaceuticals Stock Performance
Shares of scPharmaceuticals stock traded down $0.12 during midday trading on Friday, reaching $7.11. The company had a trading volume of 65,093 shares, compared to its average volume of 554,004. The company has a 50-day moving average of $7.22 and a 200-day moving average of $6.36. scPharmaceuticals Inc. it has a 52-week low of $3.68 and a 52-week high of $10.38.
Changes in analyst ratings
Several analysts have issued reports on SCPH shares. Cowen started coverage on scPharmaceuticals in a research note on Thursday, December 1st. They issued an “outperform” rating and a $25.00 target price for the company. SVB Leerink upped their target price on shares of scPharmaceuticals from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, January 27th. Finally, Cowen assumed coverage on shares of scPharmaceuticals in a research report on Thursday, December 1st. They issued an “outperform” rating and a $25.00 target price on the stock. Six analysts have rated the stock with a buy rating. The company currently has an average rating of “Buy” and a consensus target price of $18.00, according to MarketBeat.com.
scPharmaceuticals Company Profile
scPharmaceuticals, Inc is engaged in the development of transformative pharmaceuticals for subcutaneous administration. Its products include FUROSCIX, a furosemide injection used as a parenteral diuretic in the treatment of heart failure, and scCeftriaxone, used as a parenteral antibiotic outside the hospital setting.
This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider scPharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients daily. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market takes a nosedive … and scPharmaceuticals wasn’t on the list.
Although scPharmaceuticals currently has a “Buy” rating among analysts, the top-rated analysts think these five stocks are better buys.
Check out the five stocks here